Answers are grounded in this paper and cite their sources.
The development of single molecules which possess the ability to inhibit both of the membrane-bound zinc metalloproteases, angiotensin-converting enzyme EC 2.4.15.1 (ACE) and neutral endopeptidase EC 3.4.24.11 (NEP), has been the focus of much recent drug discovery effort. These agents represent a new class of cardiovascular agent that should be more effective in treating a broader range of hypertensive patient and in congestive heart failure (CHF). Dual ACE and NEP inhibitors are currently under clinical investigation for hypertension and CHF and several more are under preclinical study. This review focuses on ACE/NEP dual inhibitors reported in the patent and primary literature over the past four years.
No takes yet. Share an insight, caveat, or question.
Cynthia A. Fink (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: